Monkeypox – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Monkeypox – Drugs In Development, 2024 report and make more profitable business decisions.
Mpox, caused by the monkeypox virus, is an infectious disease presenting with a painful rash, fever, and enlarged lymph nodes. While most individuals fully recover, some may experience severe illness. Person-to-person transmission occurs through direct contact with infectious skin or lesions, including those in the mouth or genitals. Symptoms manifest from 1-21 days after exposure, lasting 2-4 weeks or longer in individuals with weakened immune systems. Diagnosis involves detecting viral DNA with a polymerase chain reaction (PCR) test. Treatment focuses on rash care, pain management, and complication prevention. Early supportive care is crucial. Vaccination is a preventive measure against mpox.
The Monkeypox drugs in development market research report provide comprehensive information on the therapeutics under development for Monkeypox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Monkeypox and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Monkeypox | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 22 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Monkeypox therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Monkeypox pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Monkeypox treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Asterivir SABavarian Nordic AS
Beijing Institute of Biological Products
BioNTech SE
Bioxytran Inc
Blue Water Biotech Inc
Emergex Vaccines Holding Ltd
EpiVax Inc
GeoVax Labs Inc
Hyundai Bioscience Co Ltd
Innovation Pharmaceuticals Inc
Moderna Inc
NanoViricides Inc
NightHawk Biosciences Inc
SIGA Technologies Inc
Stemirna Therapeutics Ltd
Tonix Pharmaceuticals Holding Corp
Vernagen Inc
Wuhan Binhui Biopharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Monkeypox reports